Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Emma on +44 1494 818005 or emma@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Emma Hardy
Recruitment Consultant
emma@zenopa.com
+44 1494 818005

Testimonials
From the beginning of the process my Account Manager kept me informed at all times and helped me with interview techniques. They checked my presentation and made suggestions of changes.
Jeanette, 2013

Shire and Heptares agree licensing deal over CNS drug

22 March 2012 00:00 in Pharmaceutical Company Product News


Shire has acquired the rights to an innovative new therapy for central nervous system (CNS) disorders from Heptares Therapeutics.

The agreement will see an operating company of Shire licensing a novel adenosine A2A antagonist discovered by Heptares for worldwide development and commercialisation, in exchange for payments up to $190 million (120.25 million pounds).

Adenosine A2A is a G-protein coupled receptor involved in the regulation of dopaminergic pathways in the brain.

Heptares' treatments, which are currently in preclinical development, involve an innovative new way of inhibiting this protein in order to deliver potential best-in-class performance.

Jeff Jonas, senior vice-president of research and development for specialty pharmaceuticals and regenerative medicine at Shire, said: "We look forward to a fruitful partnership with Heptares and to advancing the programme for the benefit of patients suffering from CNS disorders."

Earlier this month, the company also agreed a deal to purchase FerroKin BioSciences, a developer of innovative haematology treatments such as the iron chelator therapy FBS0701.ADNFCR-8000103-ID-801323833-ADNFCR

Other news stories from 22/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd